Bupropion and Naltrexone in Methamphetamine Use Disorder.

ABSTRACT:

Background

The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.

Methods

We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a sequential parallel comparison design to evaluate the efficacy and safety of extended-release injectable naltrexone (380 mg every 3 weeks) plus oral extended-release bupropion (450 mg per day) in adults with moderate or severe methamphetamine use disorder. In the first stage of the trial, participants were randomly assigned in a 0.26:0.74 ratio to receive naltrexone-bupropion or matching injectable and oral placebo for 6 weeks. Those in the placebo group who did not have a response in stage 1 underwent rerandomization in stage 2 and were assigned in a 1:1 ratio

SUBMITTER: Trivedi MH 

PROVIDER: S-EPMC8111570 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature